...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: OUCH!!! Things Move Faster In The Cancer Arena and Other Gems

BC, I thought you sold out of your RVX shares?   Zenith shares are worth more anyways , just look at Payzone  example of gilead buyout of Immunmedics for 21 Billion usd , what is Zenith work with a successful trial of ZEN3694 ????

Share
New Message
Please login to post a reply